INTEGRA LIFESCIENCES SERVICES (FRANCE) : revenue, balance sheet and financial ratios

INTEGRA LIFESCIENCES SERVICES (FRANCE) is a French company founded 19 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in SAINT-PRIEST (69800), this company of category PME shows in 2024 a revenue of 24.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - INTEGRA LIFESCIENCES SERVICES (FRANCE) (SIREN 492534466)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 24 165 676 € 25 826 273 € 25 616 103 € 27 150 471 € 26 671 851 € 34 143 994 € 34 564 479 € 29 195 842 € 28 399 023 €
Net income 1 884 823 € 1 537 421 € 460 836 € 661 839 € 689 654 € -585 934 € -181 359 € -1 013 542 € 1 499 903 €
EBITDA -8 554 856 € -8 112 843 € -8 171 027 € -5 188 627 € -4 020 678 € -5 958 062 € -7 641 722 € -9 036 709 € -7 587 840 €
Net margin 7.8% 6.0% 1.8% 2.4% 2.6% -1.7% -0.5% -3.5% 5.3%

Revenue and income statement

In 2024, INTEGRA LIFESCIENCES SERVICES (FRANCE) achieves revenue of 24.2 M€. Activity remains stable over the period (CAGR: -2.0%). Slight decline of -6% vs 2023. After deducting consumption (9.5 M€), gross margin stands at 14.7 M€, i.e. a rate of 61%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -8.6 M€, representing -35.4% of revenue. Warning negative scissor effect: despite revenue change (-6%), EBITDA varies by -5%, reducing margin by 4.0 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.9 M€, i.e. 7.8% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

24 165 676 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

14 679 174 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-8 554 856 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

2 809 968 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 884 823 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

-35.4%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 20%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 37%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.8 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 8.4% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

19.575%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

36.516%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

8.445%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.792

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

7.3%

Solvency indicators evolution
INTEGRA LIFESCIENCES SERVICES (FRANCE)

Sector positioning

Debt ratio
19.57 2024
2022
2023
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Average +15 pts over 3 years

In 2024, the debt ratio of INTEGRA LIFESCIENCES SERV... (19.57) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
36.52% 2024
2022
2023
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Average -11 pts over 3 years

In 2024, the financial autonomy of INTEGRA LIFESCIENCES SERV... (36.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
0.79 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 1.09 years
Average +13 pts over 3 years

In 2024, the repayment capacity of INTEGRA LIFESCIENCES SERV... (0.79) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 190.89. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

190.886

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-0.049

Liquidity indicators evolution
INTEGRA LIFESCIENCES SERVICES (FRANCE)

Sector positioning

Liquidity ratio
190.89 2024
2022
2023
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Average

In 2024, the liquidity ratio of INTEGRA LIFESCIENCES SERV... (190.89) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-0.05x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.41x
Q3: 6.25x
Average

In 2024, the interest coverage of INTEGRA LIFESCIENCES SERV... (-0.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 160 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 130 days. The company must finance 30 days of gap between collections and payments. Overall, WCR represents 131 days of revenue, i.e. 8.8 M€ to permanently finance.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

8 776 249 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

160 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

130 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

131 j

WCR and payment terms evolution
INTEGRA LIFESCIENCES SERVICES (FRANCE)

Positioning of INTEGRA LIFESCIENCES SERVICES (FRANCE) in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of INTEGRA LIFESCIENCES SERVICES (FRANCE) is estimated at 3 707 366 € (range 1 910 285€ - 11 615 450€). The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
1910k€ 3707k€ 11615k€
3 707 366 € Range: 1 910 285€ - 11 615 450€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

Revenue Multiple 30%
24 165 676 € × 0.21x
Estimation 5 146 670 €
2 790 917€ - 15 589 349€
Net Income Multiple 20%
1 884 823 € × 0.8x
Estimation 1 548 412 €
589 337€ - 5 654 603€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare INTEGRA LIFESCIENCES SERVICES (FRANCE) with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about INTEGRA LIFESCIENCES SERVICES (FRANCE)

What is the revenue of INTEGRA LIFESCIENCES SERVICES (FRANCE) ?

The revenue of INTEGRA LIFESCIENCES SERVICES (FRANCE) in 2024 is 24.2 M€.

Is INTEGRA LIFESCIENCES SERVICES (FRANCE) profitable?

Yes, INTEGRA LIFESCIENCES SERVICES (FRANCE) generated a net profit of 1.9 M€ in 2024.

Where is the headquarters of INTEGRA LIFESCIENCES SERVICES (FRANCE) ?

The headquarters of INTEGRA LIFESCIENCES SERVICES (FRANCE) is located in SAINT-PRIEST (69800), in the department Rhone.

Where to find the tax return of INTEGRA LIFESCIENCES SERVICES (FRANCE) ?

The tax return of INTEGRA LIFESCIENCES SERVICES (FRANCE) is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does INTEGRA LIFESCIENCES SERVICES (FRANCE) operate?

INTEGRA LIFESCIENCES SERVICES (FRANCE) operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.